Company News
Company News
Core One Labs Completes Strategic Acquisition of Awakened Biosciences and its Game-Changing Provisional Patents
February 11, 2022
Vancouver, British Columbia, Canada – February 11, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
Core One Labs Expects Imminent Breakthrough to Produce NMT, Precursor to DMT
February 10, 2022
Vancouver, British Columbia, Canada – February 10, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU)...
Read more
Company News
Core One Labs’ Successful Patent Application Filing for Protection of its Biosynthetic Production System for Psilocybin Marks a Significant Milestone for the Progression of Psychedelic Health Care
February 09, 2022
Vancouver, British Columbia, Canada – February 9, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
Core One Labs’ Akome Biotech Signs Research Agreement with University of Barcelona, Faculty of Pharmacy and Food Sciences
January 25, 2022
Vancouver, British Columbia, Canada – January 26, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
Core One Labs Announces Successful Proof of Concept and Files Patent for Protection of its Recombinant Production System for Optimized Biosynthesis of Psilocybin
January 21, 2022
Vancouver, British Columbia, Canada – January 21, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that its wholly...
Read more
Company News
Core One Labs Special Investor Webcast Rescheduled to Friday, January 21, 2022
January 18, 2022
Vancouver, British Columbia, Canada – January 18, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) announces that the special investor webcast...
Read more